Home › Compare › TIPGF vs MRK

TIPGF vs MRK: Dividend Comparison 2026

TIPGF yields 29806.26% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TIPGF wins by $2.768790497324278e+21M in total portfolio value
10 years
TIPGF
TIPGF
● Live price
29806.26%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.768790497324278e+21M
Annual income
$2,750,636,863,944,010,600,000,000,000.00
Full TIPGF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — TIPGF vs MRK

📍 TIPGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTIPGFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TIPGF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TIPGF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TIPGF
Annual income on $10K today (after 15% tax)
$2,533,532.04/yr
After 10yr DRIP, annual income (after tax)
$2,338,041,334,352,408,800,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, TIPGF beats the other by $2,338,041,334,352,408,800,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TIPGF + MRK for your $10,000?

TIPGF: 50%MRK: 50%
100% MRK50/50100% TIPGF
Portfolio after 10yr
$1.384395248662139e+21M
Annual income
$1,375,318,431,972,005,300,000,000,000.00/yr
Blended yield
99.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TIPGF
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TIPGF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTIPGFMRK
Forward yield29806.26% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$2.768790497324278e+21M$30.7K ✓
Annual income after 10y$2,750,636,863,944,010,600,000,000,000.00 ✓$950.29
Total dividends collected$2.767596035729236e+21M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TIPGF vs MRK ($10,000, DRIP)

YearTIPGF PortfolioTIPGF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,991,326$2,980,625.93$11,192$351.54+$2.98M → TIPGF
2$836,473,956$833,273,237.45$12,524$392.70+$836.46M → TIPGF
3$218,662,165,294$217,767,138,161.13$14,015$438.65+$218662.15M → TIPGF
4$53,436,192,447,135$53,202,223,930,270.30$15,682$489.96+$53436192.43M → TIPGF
5$12,208,060,591,185,060$12,150,883,865,266,626.00$17,547$547.23+$12208060591.17M → TIPGF
6$2,607,452,633,719,056,400$2,594,390,008,886,488,600.00$19,632$611.16+$2607452633719.04M → TIPGF
7$520,660,551,500,964,100,000$517,870,577,182,884,700,000.00$21,963$682.53+$520660551500964.13M → TIPGF
8$97,201,286,836,816,670,000,000$96,644,180,046,710,640,000,000.00$24,571$762.18+$97201286836816672.00M → TIPGF
9$16,966,012,504,922,880,000,000,000$16,862,007,128,007,485,000,000,000.00$27,486$851.08+$16966012504922880000.00M → TIPGF
10$2,768,790,497,324,278,000,000,000,000$2,750,636,863,944,010,600,000,000,000.00$30,745$950.29+$2.768790497324278e+21M → TIPGF

TIPGF vs MRK: Complete Analysis 2026

TIPGF — Stock

Titan Petrochemicals Group Limited, together with its subsidiaries, engages in trading various bulk commodities in the People's Republic of China and other Asia Pacific countries. It trades in oil, petrochemical, and other related products; manufactures and sells steel structures; and provides shipbuilding and repairing services. The company was formerly known as Titan (Holdings) Limited and changed its name to Titan Petrochemicals Group Limited in May 2004. The company was incorporated in 1998 and is based in Wan Chai, Hong Kong.

Full TIPGF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this TIPGF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TIPGF vs SCHDTIPGF vs JEPITIPGF vs OTIPGF vs KOTIPGF vs MAINTIPGF vs JNJTIPGF vs ABBVTIPGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.